fluoxetine has been researched along with Long QT Syndrome in 18 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Forty patients with major depressive disorder (according to DSM-III-R criteria) were enrolled in a 6-week double-blind parallel group study of fluoxetine (N = 20) or doxepin (N = 20)." | 9.08 | Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. ( Baker, B; Dorian, P; Irvine, MJ; Mitchell, J; Sandor, P; Schell, C; Shapiro, C, 1997) |
| "Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 5.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
| " Forty patients with major depressive disorder (according to DSM-III-R criteria) were enrolled in a 6-week double-blind parallel group study of fluoxetine (N = 20) or doxepin (N = 20)." | 5.08 | Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. ( Baker, B; Dorian, P; Irvine, MJ; Mitchell, J; Sandor, P; Schell, C; Shapiro, C, 1997) |
| "Drug-induced long QT syndrome is generally ascribed to inhibition of the cardiac rapid delayed rectifier potassium current (IKr)." | 1.39 | Slow delayed rectifier potassium current blockade contributes importantly to drug-induced long QT syndrome. ( Blom, MT; Klemens, CA; Langendijk, PN; Tan, HL; van Ginneken, AC; Veerman, CC; Verkerk, AO; Wilders, R, 2013) |
| "Fluoxetine (Prozac) was more potent at blocking hERG 1a/1b than 1a channels, yielding a corresponding reduction in the safety margin." | 1.37 | hERG subunit composition determines differential drug sensitivity. ( Abi-Gerges, N; Holkham, H; Jones, EM; Pollard, CE; Robertson, GA; Valentin, JP, 2011) |
| "Fluoxetine is a potent inhibitor of CYP2D6, and imipramine is metabolized by CYP2D6." | 1.33 | QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. ( Blackmon, CL; Nykamp, DL; Roberson, AG; Schmidt, PE, 2005) |
| "Fluoxetine is an antidepressant drug, only recently discovered to be a QT interval prolonging agent." | 1.33 | Prolonged QT interval in an infant of a fluoxetine treated mother. ( Dubnov, G; Fogelman, R; Merlob, P, 2005) |
| "Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 1.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| He, S | 1 |
| Moutaoufik, MT | 1 |
| Islam, S | 1 |
| Persad, A | 1 |
| Wu, A | 1 |
| Aly, KA | 1 |
| Fonge, H | 1 |
| Babu, M | 1 |
| Cayabyab, FS | 1 |
| Wei, A | 1 |
| Peng, J | 1 |
| Gu, Z | 1 |
| Li, J | 1 |
| Rizzo, R | 1 |
| Gulisano, M | 1 |
| Calì, PV | 1 |
| Di Pino, A | 1 |
| Peters, S | 1 |
| Veerman, CC | 1 |
| Verkerk, AO | 1 |
| Blom, MT | 1 |
| Klemens, CA | 2 |
| Langendijk, PN | 1 |
| van Ginneken, AC | 1 |
| Wilders, R | 1 |
| Tan, HL | 1 |
| Yeung, KS | 1 |
| Meanwell, NA | 1 |
| Abi-Gerges, N | 1 |
| Holkham, H | 1 |
| Jones, EM | 1 |
| Pollard, CE | 1 |
| Valentin, JP | 1 |
| Robertson, GA | 1 |
| Jaffe, R | 1 |
| Leavitt, R | 1 |
| Wind, T | 1 |
| Nykamp, DL | 1 |
| Blackmon, CL | 1 |
| Schmidt, PE | 1 |
| Roberson, AG | 1 |
| Dubnov, G | 1 |
| Fogelman, R | 1 |
| Merlob, P | 1 |
| Wilting, I | 1 |
| Smals, OM | 1 |
| Holwerda, NJ | 1 |
| Meyboom, RH | 1 |
| de Bruin, ML | 1 |
| Egberts, TC | 1 |
| Adetunji, B | 1 |
| Basil, B | 1 |
| Mathews, M | 1 |
| Osinowo, T | 1 |
| Hancox, JC | 2 |
| Mitcheson, JS | 1 |
| Rajamani, S | 1 |
| Eckhardt, LL | 1 |
| Valdivia, CR | 1 |
| Gillman, BM | 1 |
| Anderson, CL | 1 |
| Holzem, KM | 1 |
| Delisle, BP | 1 |
| Anson, BD | 1 |
| Makielski, JC | 1 |
| January, CT | 1 |
| Baker, B | 1 |
| Dorian, P | 1 |
| Sandor, P | 1 |
| Shapiro, C | 1 |
| Schell, C | 1 |
| Mitchell, J | 1 |
| Irvine, MJ | 1 |
| Lherm, T | 1 |
| Lottin, F | 1 |
| Larbi, D | 1 |
| Bray, M | 1 |
| Legall, C | 1 |
| Caen, D | 1 |
| Varriale, P | 1 |
| Witchel, HJ | 1 |
| Pabbathi, VK | 1 |
| Hofmann, G | 1 |
| Paul, AA | 1 |
2 reviews available for fluoxetine and Long QT Syndrome
| Article | Year |
|---|---|
HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Carcinogenesis; Cell Movement; Cell Proliferation; | 2020 |
QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Defibrillators, Implantable; Drug Inter | 2017 |
1 trial available for fluoxetine and Long QT Syndrome
| Article | Year |
|---|---|
Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disord | 1997 |
15 other studies available for fluoxetine and Long QT Syndrome
| Article | Year |
|---|---|
Mandatory electrocardiographic monitoring in young patients treated with psychoactive drugs.
Topics: Antipsychotic Agents; Child; Electrocardiography; Fluoxetine; Humans; Long QT Syndrome; Male; Pimozi | 2013 |
QRS fragmentation in acquired long QT syndrome does not always predict torsades of pointes tachycardia: a case report.
Topics: Antidepressive Agents, Second-Generation; Diagnosis, Differential; Electrocardiography; Female; Fluo | 2014 |
Slow delayed rectifier potassium current blockade contributes importantly to drug-induced long QT syndrome.
Topics: Action Potentials; Cells, Cultured; Computer Simulation; Echocardiography; Electrocardiography; Exer | 2013 |
Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Humans; Inhibitory Concentrati | 2008 |
hERG subunit composition determines differential drug sensitivity.
Topics: Action Potentials; Arrhythmias, Cardiac; Cell Line, Transformed; Drug Evaluation, Preclinical; Ether | 2011 |
QTc prolongation in multiple drug overdose.
Topics: Adult; Bupropion; Drug Overdose; Fluoxetine; Humans; Long QT Syndrome; Male; Piperazines; Psychotic | 2004 |
QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.
Topics: Anti-Infective Agents, Urinary; Antidepressive Agents; Cytochrome P-450 CYP2D6 Inhibitors; Drug Syne | 2005 |
Prolonged QT interval in an infant of a fluoxetine treated mother.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Electrocardiography; Female; Fluoxeti | 2005 |
QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine.
Topics: Aged, 80 and over; Female; Fluoxetine; Humans; Long QT Syndrome; Selective Serotonin Reuptake Inhibi | 2006 |
Should the Physician's Desk Reference contraindicate the use of chlorpromazine-fluoxetine combination? A case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chlorpromazine; Contraindicat | 2006 |
Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.
Topics: Antidepressive Agents, Second-Generation; Drug Overdose; Ether-A-Go-Go Potassium Channels; Female; F | 2006 |
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Blotting, Western; Cell Line; Cell Membrane; Cisapr | 2006 |
[Torsade de pointes after poisoning with fluoxetine alone].
Topics: Adult; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Electrocardiograp | 2000 |
Fluoxetine (Prozac) as a cause of QT prolongation.
Topics: Depression; Electrophysiology; Fluoxetine; Humans; Long QT Syndrome; Male; Middle Aged; Selective Se | 2001 |
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.
Topics: Animals; Calcium Channels, L-Type; Cation Transport Proteins; Citalopram; Ether-A-Go-Go Potassium Ch | 2002 |